Stryker Corporation (SYK) Gains Strength From Procedure Volumes and Capital Equipment Backlog

Stryker Corporation (SYK) is showing strength due to high procedure volumes and a significant capital equipment demand backlog, as highlighted by recent analyst upgrades. Barclays raised its price target to $469 with an Overweight rating, while Needham reiterated a Buy rating and increased its price target to $454, both recognizing the company’s strong performance across its MedSurg, Neurotechnology, and Orthopaedic segments. The company’s innovative medical technology solutions are driving its positive outlook.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)